View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 12, 2022

Moderna doses first subjects in Phase I/II trial of influenza vaccines

The trial will enrol 560 participants to assess safety, reactogenicity and immunogenicity of mRNA-1020 or mRNA-1030 vaccines.

Moderna has dosed the first subjects in a Phase I/II clinical trial of its seasonal influenza vaccine candidates, mRNA-1020 and mRNA-1030. 

Both the messenger RNA (mRNA) vaccines act on hemagglutinin and neuraminidase antigens, which are two key influenza surface glycoproteins needed across the life cycle of the virus.

The randomised, dose-ranging, observer-blind trial will analyse the safety, reactogenicity and immunogenicity of one dose of mRNA-1020 or mRNA-1030 in healthy adult subjects of the age 18 years and above in the US.

This trial is expected to enrol nearly 560 subjects.

Both vaccines comprise eight mRNAs each that act on both hemagglutinin and neuraminidase at varying doses and ratios. 

Like influenza vaccine candidate of Moderna, mRNA-1010, they will target the World Health Organization (WHO) recommended strains to prevent influenza, including seasonal influenza A/H1N1, A/H3N2 and influenza B/Yamagata and B/Victoria. 

The company is pursuing an iterative method for the development of influenza vaccines, with higher levels of enhancements intended to boost immune responses and immunologic breadth. 

Though influenza vaccines licenced presently act mainly on the viral HA, in the Phase I/II trial, Moderna adds neuraminidase antigens to mRNA-1020/1030 vaccines to target both glycoproteins to offer a strong antibody response.

Moderna CEO Stéphane Bancel said: “We are pleased to apply Moderna’s mRNA platform to address the longstanding design and manufacturing challenges associated with developing seasonal influenza vaccines. 

“We believe that by targeting both hemagglutinin and neuraminidase, we can achieve broader immunity and higher vaccine efficacy against circulating influenza strains than traditional influenza vaccines.”

In March this year, the company reported that the Phase II/III KidCOVE trial of its Covid-19 vaccine, mRNA-1273, in children of the age six months to under six years met the primary endpoint.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU